HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.

AuthorsM K de Vries, E Brouwer, I E van der Horst-Bruinsma, A Spoorenberg, J C van Denderen, A Jamnitski, M T Nurmohamed, B A C Dijkmans, L A Aarden, G J Wolbink
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 68 Issue 11 Pg. 1787-8 (Nov 2009) ISSN: 1468-2060 [Electronic] England
PMID19822712 (Publication Type: Letter, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Anti-Idiotypic
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Adalimumab
Topics
  • Adalimumab
  • Adult
  • Antibodies, Anti-Idiotypic (biosynthesis)
  • Antibodies, Monoclonal (immunology, therapeutic use)
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents (immunology, therapeutic use)
  • Drug Tolerance
  • Female
  • Humans
  • Male
  • Middle Aged
  • Spondylitis, Ankylosing (drug therapy, immunology)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: